在糖尿病管理中的基于水凝的药物输送系统
Renu Saharan1, Jaspreet Kaur1, Sanchit Dhankhar2,3
1Department of Pharmaceutical sciences, M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala (Haryana), India.
Pharmaceutical nanotechnology
|October 11, 2023
概括
基于生物聚合物的水凝为糖尿病治疗提供了一种新的方法. 这些先进的材料可以持续释放口服低血糖药物,克服了DM常规疗法的局限性.
科学领域:
- 生物材料科学 生物材料科学
- 聚合物化学 聚合物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病 (DM) 影响全球超过2亿人,其特点是胰岛素的作用或分泌受损.
- 1型和2型糖尿病很常见,而2型糖尿病通常由口服低血糖药物控制.
- 传统的口服低血糖药面临诸如频繁剂量和低生物可用性等挑战.
研究的目的:
- 审查最近生物聚合物水凝在口服低血糖药物输送的进展.
- 探索使用交叉连接的水凝和水凝涂层,以持续释放药物.
- 为了解决与传统口服低血糖剂型相关的局限性.
主要方法:
- 在著名的科学数据库中进行文献搜索:PubMed,Elsevier和Google Scholar.
- 专注于关于生物聚合物水凝及其在药物输送中的应用的研究和评论.
- 分析水凝特性及其适用于口服低血糖药物可控释放的适用性.
主要成果:
- 基于生物聚合物的水凝是具有高含水量和生物相容性的3D交联网络.
- 它们的特性模仿软活体组织,使得它们非常适合生物医学应用.
- 水凝作为药物运输和控制释放的有效平台,具有作为植入物涂层的潜力.
结论:
- 生物聚合物水凝代表了持续口服低血糖输送的有希望的策略.
- 物理和化学交联的水凝,包括涂料,为传统剂型的缺点提供了解决方案.
- 本次审查强调了用于改善糖尿病管理的水凝技术的创新.
相关概念视频
01:15Diabetes: Management and Pharmacotherapy
290
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
290
01:27Insulin Formulations: Types and Delivery
205
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
205
01:06Oral Hypoglycemic Agents: Glinides
162
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
162
01:22Drug Delivery: Miscellaneous Routes
361
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
361
01:22Diabetes Mellitus: Overview and Type I Subtype
2.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.7K
01:24Glucagon-like Receptor Agonists
334
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
334